Before I get to the investment aspects of today’s article, let’s first experience an LSD flashback. Past is often prologue.

Imagine how world history might have changed, if Grace Slick had succeeded in her mission to send Tricky Dick on an acid trip.

My favorite female singer, Grace Slick of the 1960s psychedelic rock group Jefferson Airplane, was a counterculture rebel but also a child of blue blood privilege. Her father was an investment banker, and she’s a lineal descendant of passengers who came over on the Mayflower.

Grace attended Finch College in New York City, a women’s finishing school for the elite. Grace’s schoolmate was Tricia Nixon, whose dad became America’s 37th president.

Hence the invitation Grace received in 1970 to attend a White House tea party for Finch alumni. Grace showed up with a vial of LSD, which she planned to slip into President Nixon’s teacup. Alas, Grace was spotted at the gate by the Secret Service, who realized that she was the hallucinogen-loving rock star who penned the drug anthem White Rabbit. She was thrown out.

Fast forward to 2023. The establishment is embracing LSD and psychedelics. Corporate executives, high-ranking politicians, and Wall Street investors are extolling the medical and financial virtues of these mind-bending substances. Nixon would be appalled.

The psychedelics era has been reborn. I explain the money-making opportunities, below.

The most dangerous man in America…

President Nixon’s War on Drugs, launched in 1971, was a tactic devised by the White House to persecute the paranoid president’s perceived enemies. Nixon once called LSD guru Timothy Leary “the most dangerous man in America.” However, the war failed and it’s currently getting dismantled. Nixon resigned in disgrace, whereas Leary’s research is getting rediscovered.

Consider Johns Hopkins, the gold standard in medical care and research. Johns Hopkins recently opened a new center for psychedelic research. The center, with $17 million from donors, aims to give psychedelic-based medicines a foothold in mainstream medicine. The center initiates research with psychedelics in what it calls “healthy, psychedelic-naive volunteers.”

The following tweet shows an example of the center’s clinical activities:

LSD, psilocybin mushrooms, MDMA, mescaline, ketamine, ayahuasca, and several other psychedelics are a major focus of medical research around the world, for the treatment of a wide range of physical and psychological ailments. A new industry is emerging that’s rife with investment possibilities.

Pharmaceutical companies are forming, most of them clinical stage micro-caps, to develop psychedelics-based treatments for various medical challenges such as the opioid crisis.

Just as we witnessed a legalization wave for marijuana, we’re now witnessing one for LSD and other hallucinogens.

This week, a Rhode Island House committee approved a bill that would legalize possession and cultivation of psilocybin mushrooms. The next stop for the bill will be the House floor, where it’s expected to get a favorable reception.

Last month, a California bill to legalize the possession of certain psychedelics and to facilitate their use passed the Senate.

Read This Story: Things Get Trippy in California

The legislation now heads to the Assembly for consideration, where it’s expected to pass. If the bill legalizing psychedelics passes both chambers, Gov. Gavin Newsom (D) is expected to sign it.

In the November 2022 midterm elections, Colorado voters approved a ballot initiative to remove criminal penalties for the possession of psilocybin and other psychedelic drugs. The new law took effect in January 2023. The Centennial State joined several jurisdictions around the U.S. that have already legalized psychedelics.

Denver was the first jurisdiction in the U.S. to legalize magic mushrooms. The historic legal change enacted on May 7, 2019 in the Mile High City triggered a cultural earthquake throughout the country and spawned an exciting investment theme. In California, Oakland in 2019 and Santa Cruz in 2020 followed Denver’s example. Similar measures are pending, from coast to coast.

The global market for psychedelic drugs is expected to grow to nearly $12 billion annually by 2029, up from $4.87 billion in 2022, according to a recent report by Brandessence Market Research.

More than 50 psychedelics companies have gone public so far in the U.S., with a collective valuation of more than $2 billion. From an investment standpoint, that sounds like my cup of tea.

John Persinos is the chief investment strategist of Marijuana Profit Alert, a trading service that pinpoints the best investments in the marijuana and psychedelics industries. To learn more, visit this URL.

Subscribe to John’s video channel: